Stock A141080 LIGACHEM BIOSCIENCES INC.
Add to a list
To use this feature you must be a member
Log inSign up

LigaChem Biosciences Inc. Stock

Equities

A141080

KR7141080002

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
65,500 KRW -1.06% Intraday chart for LigaChem Biosciences Inc. +2.50% +0.77%
Apr. 08 NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024 CI
Mar. 29 Pan Orion Corp. Ltd. completed the acquisition of 4.93% stake in LegoChem Biosciences, Inc. from Kim Yong Ju and Park Se Jin. CI

Financials

Sales 2024 * 128B 93.06M Sales 2025 * 81B 58.89M Capitalization 2,354B 1.71B
Net income 2024 * 4B 2.91M Net income 2025 * -51B -37.08M EV / Sales 2024 * 15.2 x
Net cash position 2024 * 414B 301M Net cash position 2025 * 464B 337M EV / Sales 2025 * 23.3 x
P/E ratio 2024 *
-53.3 x
P/E ratio 2025 *
-149 x
Employees 135
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.56%
More Fundamentals * Assessed data

Chart LigaChem Biosciences Inc.

Dynamic Chart

Latest news about LigaChem Biosciences Inc.

NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024 CI
Pan Orion Corp. Ltd. completed the acquisition of 4.93% stake in LegoChem Biosciences, Inc. from Kim Yong Ju and Park Se Jin. CI
LegoChem Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Samsung Biologics Collaborates with LegoChem Biosciences on ADC Development and Manufacturing MT
Orion Set to Acquire 25% Stake in LegoChem Biosciences MT
South Korean Shares Close Lower Amid Geopolitical Tension MT
Legochem Biosciences to Raise 469.8 Billion Won through Rights Issue; Shares Fall 5% MT
LegoChem Biosciences, Inc. announced that it expects to receive KRW 1018.327793998 billion in funding from Pan Orion Corp. Ltd. CI
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023. CI
LegoChem Biosciences, Inc.'s Equity Buyback announced on June 28, 2023, has expired with 140,000 shares, representing 0.53% for KRW 4,879.08 million. CI
J&J: licensing agreement with Korea's LegoChem in ADCs CF
Legochem Biosciences Announces License Agreement for Lcb84 Trop2-Targeted ADC CI
LegoChem Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
BostonGene and LegoChem Biosciences, Inc. Announce Collaboration to Support Phase I/II Study of LCB84, TROP2-Directed ADC, in Patients with Advanced Cancers CI
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023. CI
More news

Press releases LigaChem Biosciences Inc.

Samsung Biologics partners with LegoChem Biosciences for ADC development and manufacturing AQ
LegoChem Biosciences Selects BostonGene as Genomic Partner for First-in-Human Clinical Trial AQ
LegoChem Biosciences : WuXi XDC and LegoChem Biosciences sign Memorandum of Understanding AQ
Legochem Biosciences : CStone and LegoChem Biosciences Enter Global Licensing Agreement for New Antibody Drug Conjugate AQ
LegoChem Biosciences : and Takeda Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates in Immuno-Oncology BU
More press releases

News in other languages on LigaChem Biosciences Inc.

J&J : accord de licence avec le coréen LegoChem dans les ADC
LATE BRIEFING - Unternehmen und Märkte
EN DIRECTO DESDE LOS MERCADOS: ACS, Santander, Rovi, Sacyr, Meta, Nokia, Airbus, Shopify, AXA, Givaudan, Sika, Atlantia...
Epic Games recauda 2.000 millones de dólares y eleva su valoración a 31.500 millones de dólares
LEGO : 1 milliards de dollars de bénéfice trimestriel, loin devant Hasbro
More news

Quotes and Performance

1 day-1.06%
1 week+2.50%
Current month-12.43%
1 month-10.27%
3 months+24.76%
6 months+82.45%
Current year+0.77%
More quotes

Highs and lows

1 week
62 300.00
Extreme 62300
69 000.00
1 month
58 800.00
Extreme 58800
78 800.00
Current year
46 350.00
Extreme 46350
84 000.00
1 year
31 200.00
Extreme 31200
84 000.00
3 years
30 050.00
Extreme 30050
84 000.00
5 years
16 500.00
Extreme 16500
84 000.00
10 years
7 175.00
Extreme 7175
84 000.00
More quotes

Managers and Directors - LigaChem Biosciences Inc.

Managers TitleAgeSince
Yong-Zu Kim CEO
 Chief Executive Officer 67 06-05-01
Se-Jin Park DFI
 Director of Finance/CFO 62 -
Chang-Sun Lee CTO
 Chief Tech/Sci/R&D Officer 58 -
Members of the board TitleAgeSince
Yong-Zu Kim CEO
 Chief Executive Officer 67 06-05-01
Se-Jin Park DFI
 Director of Finance/CFO 62 -
Young-Lag Cho BRD
 Director/Board Member 58 -
More insiders

ETFs positioned on LigaChem Biosciences Inc.

Name Weight AuM 1st Jan change Investor Rating
SIMPLIFY EMERGING MARKETS PLUS DOWNSIDE CONVEXITY ETF - USD ETF Simplify Emerging Markets Plus Downside Convexity ETF - USD
0.01% 4 M€ -4.41% -
LEADERSHARES EQUITY SKEW ETF - USD ETF LeaderShares Equity Skew ETF - USD
0.00% 117 M€ +1.11% -
More ETFs positioned on LigaChem Biosciences Inc.

Quotes

Date Price Change Volume
24-04-26 65,500 -1.06% 413,368
24-04-25 66,200 -2.93% 362,945
24-04-24 68,200 +0.59% 534,214
24-04-23 67,800 +7.28% 1,303,510
24-04-22 63,200 -1.10% 631,404

End-of-day quote Korea S.E., April 25, 2024

More quotes

Company Profile

LigaChem Biosciences Inc, formerly LegoChem Biosciences Inc, is a Korea-based biotechnology company mainly engaged in development and discovery of new pharmaceuticals based on medical chemistry. The Company principally involves in the development of new drugs, including antibiotics, anticoagulants, anticancer, antiplatelet, anti-inflammatory, as well as antibody-drug-conjugates (ADC), among others. The Company provides technology transfer, joint and contact research and research services. In addition, the Company sells pharmaceutical products.
Sector
Biotechnology & Medical Research
Calendar
2024-05-13 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for LigaChem Biosciences Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
LIGACHEM BIOSCIENCES INC. Stock LigaChem Biosciences Inc.
+0.77% 1.73B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.71B
ARGENX SE Stock argenx SE
+1.69% 22.02B
BIONTECH SE Stock BioNTech SE
-17.37% 20.9B
GENMAB A/S Stock Genmab A/S
-9.30% 17.85B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.21B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 15.52B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.86B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.04B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. A141080 Stock